SOAT1 and Dravet syndrome: For JAK/STAT mutations, the JAK1/2 inhibitors, ruxolitinib and momelotinib, have been investigated and are now FDA-approved for myelofibrosis [38], and researchers remain optimistic that their use in myelofibrosis can pave the way for ML-DS treatment as well.